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!
Faced	with	the	compound	uncertainties	of	Brexit,	the	attention	of	the	UK	science	
community	has	understandably	focused	on	two	big-ticket	items:	mobility	and	money.	
But	there’s	a	third	“m”	that	will	demand	closer	attention	as	the	Article	50	negotiations	
get	underway:	the	machinery	of	scientific,	technical	and	regulatory	advice.	Fuelled	for	
decades	by	pan-European	cooperation,	the	smooth	running	of	this	machinery	at	a	UK	
level	may	stutter	or	fail	altogether	in	crucial	areas	such	as	clinical	trials,	air	quality,	food	
standards,	nuclear	safety	and	the	regulation	of	new	technologies.		
	
Across	Europe,	claims	that	people	have	had	“enough	of	experts”	coexist	with	moves	to	
strengthen	institutions	and	processes	for	evidence-informed	policymaking.	Much	of	this	
effort	is	directed	towards	regulatory	frameworks	or	technical	standards	–	what	Sheila	
Jasanoff	memorably	dubbed	the	“fifth	branch”	of	government.		
	
The	UK’s	new	Department	for	Exiting	the	EU	(DExEU)	has	earmarked	fifty-seven	policy	
areas	that	will	be	significantly	affected	by	Brexit.	In	some	of	these,	the	UK	depends	on	
EU-wide	networks	of	expertise	and	regulatory	oversight;	in	others,	the	relationship	is	
one	of	mutual	interdependence;	or	strengths	in	the	UK	research	base	have	shaped	
frameworks	across	the	whole	of	Europe.		
	
This	is	all	about	to	change.	Now	that	the	Article	50	gun	has	fired,	the	next	step	will	be	a	
Great	Repeal	Bill,	which	will	transfer	applicable	EU	laws	and	regulations	–	buying	the	UK	
more	time	to	unpick	any	statutory	knots	that	Brexit	will	create.		
	
Decoupling	structures	for	scientific	and	technical	advice	can,	at	first	glance,	seem	
deceptively	simple.	In	many	areas,	UK	institutions	map	onto	EU	counterparts:	the	UK	
Food	Standards	Agency	(FSA)	coexists	with	the	European	Food	Safety	Authority	(EFSA);	
the	European	Medicines	Agency	(EMA)	with	the	UK	Medicines	and	Healthcare	Products	
Regulatory	Agency	(MHRA).	Why	not	shift	responsibilities	from	Brussels	to	London	and	
let	us	Brits	get	on	with	the	job?	
	
The	difficulty	is	that	UK-EU	networks	of	expertise,	guidance	and	oversight	are	
complementary,	and	have	developed	in	tandem	over	many	years.	Generations	of	British	
scientists	and	experts	have	shaped	EU	frameworks;	and	vice	versa.	Around	every	issue	
that	is	codified	in	law	or	regulation	there	exists	a	softer	sphere	of	influence,	information	
exchange	and	standard	setting.		
	
So	in	animal	health,	EFSA	plays	an	important	role	in	coordinating	data	and	evidence	
about	emerging	livestock	diseases	on	behalf	of	all	EU	states.	The	UK	benefits	being	from	
being	part	of	a	network	of	EU	reference	laboratories,	which	coordinate	surveillance,	risk	
assessment	and	epidemiology	on	a	range	of	transboundary	diseases,	such	as	foot-and-
mouth	disease	and	avian	flu.	And	the	FSA	has	drawn	heavily	on	EFSA’s	meta-analyses	
and	sophisticated	protocols	around	risk	and	uncertainty.	
	
In	the	life	sciences,	the	UK’s	3%	share	of	the	global	pharmaceutical	market	is	dwarfed	by	
the	EU’s	25%.	This	brings	significant	benefits	from	regulatory	harmonization	through	
the	EMA	(which	–	for	now	–	has	its	890	staff	headquartered	in	London).	If	EMA	licensing	
was	no	longer	to	apply	in	the	UK,	the	Association	of	the	British	Pharmaceutical	Industry	
warns	of	delays	of	up	to	a	year	for	British	patients	looking	to	access	innovative	
treatments.		
	
In	environmental	protection,	a	recent	inquiry	by	the	UK	Environmental	Audit	
Committee	estimates	that	up	to	a	third	of	EU	legislation	will	be	difficult	to	transpose	into	
UK	law.	And	those	protections	–	for	wildlife,	habitats	and	biodiversity	–	that	can	be	
transferred	through	the	Great	Repeal	Bill,	will	then	be	detached	from	underpinning	
sources	of	expert	advice,	no	longer	updated,	with	no	UK	body	to	enforce	them.	
	
Over	time,	the	UK	can	build	up	new	advisory	and	regulatory	capacity.	But	this	won’t	be	
quick	or	easy.	And	there	are	a	handful	of	areas	where	the	reliance	on	EU-wide	structures	
is	particularly	acute.		
	
The	nuclear	research	community	was	alarmed	by	last	month’s	unexpected	
announcement	that	Brexit	would	also	require	UK	withdrawal	from	the	European	Atomic	
Energy	Community	(Euratom).	Among	Euratom’s	responsibilities	are	ensuring	nuclear	
safety	standards	and	supporting	non-proliferation.	Through	its	supply	agency,	it	also	
oversees	the	market	for	medical	radioisotopes,	such	as	molybdenum-99,	used	in	
radiotherapy	treatments	for	cancer.	Many	scientists	are	now	calling	for	the	Euratom	exit	
to	be	decoupled	from	the	Brexit	timetable,	as	its	functions	simply	can’t	be	replaced	by	
2019.	
	
A	further	issue	is	ensuring	that	UK	policymakers	have	access	to	the	best	available	
evidence	and	advice	in	support	of	the	Article	50	negotiations.	Here	there	have	been	calls	
from	the	House	of	Commons	Science	and	Technology	Committee	for	Whitehall’s	new	
Brexit	departments	to	appoint	chief	scientific	advisers.	Ministers	say	they	are	
considering	this,	but	no	appointments	have	yet	been	made.	
	
It	will	be	particularly	important	for	the	Department	for	International	Trade	to	draw	
scientific	advice	into	its	future	negotiations,	to	underpin	consumer	protection	and	
environmental	standards	–	and	avoid	any	hint	of	a	UK	race	to	the	regulatory	bottom	in	
pursuit	of	new	markets,	as	advocated	by	the	more	gung-ho	Brexiteers.	
	
These	changes	can	of	course	cut	both	ways.	Regulatory	gaps	may	become	an	
opportunity	to	cut	red	tape.	Forced	withdrawal	from	EU	expert	networks	may	create	
domestic	opportunities	for	some.	In	optimistic	moments,	some	scientific	leaders	suggest	
the	UK	could	become	a	testbed	for	more	flexible	approaches	to	new	technologies	and	
treatments	–	as	it	has	with	mitochondrial	donation.	
	
But	for	now,	these	questions	lie	a	long	way	down	the	seemingly	endless	list	of	issues	
that	need	to	be	resolved	in	less	than	24	months.	And	attention	which	has	been	paid	to	
them	is	patchy,	under-resourced	and	paralysed	by	the	high	politics	that	dictate	the	pace	
of	the	wider	Brexit	debate.	For	the	sake	of	UK	–	and	European	–	science	policy,	this	
needs	to	change	fast.	
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